• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Unspecified (PubMed=16203773).
  

PubMed=16035614; DOI=10.1007/s10585-004-6918-5
Mandic R., Ludwig T., Oberleithner H., Werner J.A.
Evaluation of head and neck squamous cell carcinoma invasiveness by the electrical resistance breakdown assay.
Clin. Exp. Metastasis 21:699-704(2004)

PubMed=16203773; DOI=10.1158/1078-0432.CCR-05-0378
Mandic R., Schamberger C.J., Muller J.F., Geyer M., Zhu L., Carey T.E., Grenman R., Dunne A.A., Werner J.A.
Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
Clin. Cancer Res. 11:6845-6852(2005)

PubMed=17312569; DOI=10.1002/hed.20478
Lin C.J., Grandis J.R., Carey T.E., Gollin S.M., Whiteside T.L., Koch W.M., Ferris R.L., Lai S.Y.
Head and neck squamous cell carcinoma cell lines: established models and rationale for selection.
Head Neck 29:163-188(2007)

PubMed=19414362
Mandic R., Rodgarkia-Dara C.J., Krohn V., Wiegand S., Grenman R., Werner J.A.
Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor.
Anticancer Res. 29:1181-1187(2009)

DOI=10.1158/1538-7445.AM2020-507
Kondratyev M.K., Pesic A., Dvorkin-Sheva A., Ketela T., Moffat J., Koritzinsky M., Wouters B.G.
Repurposing of FDA approved drugs for treatment of metastatic HNSCC.
Cancer Res. 80 Suppl. 16:507-507(2020)